Get the Stockscreener App
0.0739
37.11%
-0.0436
After Hours:
.04
-0.0339
-45.87%
Bioxcel Therapeutics Inc stock is traded at $0.0739, with a volume of 39.74M.
It is down -37.11% in the last 24 hours and down -91.41% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.1175
Open:
$0.0927
24h Volume:
39.74M
Relative Volume:
6.91
Market Cap:
$2.31M
Revenue:
$680.00K
Net Income/Loss:
$-75.33M
P/E Ratio:
-0.0119
EPS:
-6.1898
Net Cash Flow:
$-57.38M
1W Performance:
-59.26%
1M Performance:
-91.41%
6M Performance:
-95.52%
1Y Performance:
-97.93%
1-Day Range:
$0.069
$0.0935
1-Week Range:
$0.069
$0.197
52-Week Range:
$0.069
$4.29
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.0739 | 25.00M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us
symbol__ Stock Quote Price and Forecast - CNN
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity? - Yahoo Finance
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
BioXcel Therapeutics, Inc. Share Price Live Today – NASDAQ:BTAI Stock Price, Chart, News, History - Upstox
BioXcel (BTAI) Stock News & Analysis - TechStock²
Case Summary: BioXcel Therapeutics Chapter 11 - Bondoro
$BioXcel Therapeutics (BTAI.US)$ only know .135-.115 it be like that - Moomoo
$BioXcel Therapeutics (BTAI.US)$ .1055 looking secured. investor terms liquidity zone looks full.🤔🧐 - Moomoo
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) dropped from S&P TMI Index - marketscreener.com
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Secures DIP Financing Amid Nasdaq Delisting Move - TipRanks
BioXcel Therapeutics Received Notice of Delisting - TradingView
BioXcel agrees to $77M DIP as Nasdaq delists - Stock Titan
Teva Bids $57.5 Million for BioXcel's Agitation Drug in Bankruptcy Auction - finance.biggo.com
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid - Yahoo Finance
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m - Yahoo Finance
BioXcel Stock Crashes 74.8% as Teva’s $57.5 Million Bid Meets Chapter 11 - TechStock²
BioXcel Therapeutics Files Chapter 11, Lines Up $125M Teva Asset Sale - ElevenFlo
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 - benzinga.com
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel - Pharmaceutical Executive
Teva Sinks on Bid to Buy BioXcel - baystreet.ca
BioXcel Therapeutics Files Chapter 11, Agrees to Asset Sale With Teva - citybiz
Teva bids $57.5M for BioXcel’s agitation treatment asset By Investing.com - Investing.com UK
Teva Pharmaceutical Industries to Bid on BioXcel Therapeutics’ BXCL501 Dexmedetomidine Sublingual Film in Court-Supervised Sale Process - Quiver Quantitative
Teva Pharmaceutical Industries Ltd - Via Ritzau
BioXcel Therapeutics Picks Teva as Stalking Horse in $57.5M Asset Sale, Up to $87.5M in Milestones - TradingView
BioXcel Shares Sink 62% as Chapter 11 Filing Leaves Equity Subordinate to $100M–$500M Debt - TechStock²
L'azienda biofarmaceutica BioXcel Therapeutics presenta istanza di fallimento negli Stati Uniti - TradingView
Motion for Joint Administration Filed by BioXcel Therapeutics, Inc. - marketscreener.com
BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain - theglobeandmail.com
Bioxcel Therapeutics Enters Fourteenth Amendment To Credit Agreement On August 24, 2026 - TradingView
BioXcel Therapeutics Amends Oaktree-Led Credit Agreement, Extends Deadline to Restructure or Repay Debt - TradingView
ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus
BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - pulse2.com
BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan
Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan
BioXcel Therapeutics director Susan E. Atkins files initial beneficial ownership statement - Bitget
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BTAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rally 7.08%Guidance Upgrade Report - vinanet.vn
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioxcel Therapeutics Inc Stock (BTAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rodriguez Javier | See Remarks |
May 20 '26 |
Sale |
1.08 |
6,560 |
7,111 |
26,803 |
| Steinhart Richard I | Chief Financial Officer |
May 20 '26 |
Sale |
1.08 |
6,845 |
7,427 |
26,300 |
| Mehta Vimal | CEO and President |
May 20 '26 |
Sale |
1.09 |
19,419 |
21,108 |
69,598 |
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):